The persistent risk of economic uncertainty and market volatility mean that it can be worth seeking out high quality stocks for your portfolio. Safe, profitable companies with strong balance sheets can offer solid returns over the long...
EW — Edwards Lifesciences Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapHigh Flyer
- $59.77bn
- $58.87bn
- $5.23bn
- 98
- 18
- 87
- 75
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.89 | ||
| PEG Ratio (f) | 4.65 | ||
| EPS Growth (f) | 8.36% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.23 | ||
| Price to Tang. Book | 13.72 | ||
| Price to Free Cashflow | 41.84 | ||
| Price to Sales | 11.16 | ||
| EV to EBITDA | 31.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.37% | ||
| Return on Equity | 29.3% | ||
| Operating Margin | 32.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3,435.3 | 3,722.8 | 4,348 | 4,386.3 | 5,232.5 | 5,730.53 | 6,406.63 | 12.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +40.67 | +22.64 | +9.14 | +4.98 | +28.25 | +6.51 | +11.02 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for EW
The Edwards Lifesciences (NYQ:EW) share price has risen by 7.16% over the past month and it’s currently trading at 83.71. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will...
Shares in Edwards Lifesciences (NYQ:EW) are currently trading at 70.94 but the question for investors is how much the market chaos of 2020 will impact on its price. The answer comes down to judging whether Edwards Lifesciences is well...
There's an exclusive group of companies in the stock market that stand out because they've got what billionaire investor Warren Buffett calls economic moats. Like medieval castles, their profits are fortified by impregnable business mo...
Shares in Edwards Lifesciences (NYQ:EW) are currently trading at 217.47 but the question for investors is how much the market chaos of 2020 will impact on its price. The answer comes down to judging whether Edwards Lifesciences is well...
Profile Summary
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.
Directors
- Michael Mussallem CHM (68)
- Scott Ullem CFO (55)
- Jean-Luc Lemercier CEX (64)
- Donald Bobo VPR (59)
- Daveen Chopra VPR (42)
- Catherine Szyman VPR (54)
- Huimin Wang VPR (64)
- Larry Wood VPR (55)
- Martha Marsh LED (72)
- Kieran Gallahue IND (57)
- Leslie Heisz IND (60)
- Paul LaViolette IND (63)
- Steven Loranger IND (69)
- Ramona Sequeira IND (55)
- Nicholas Valeriani IND (64)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- September 10th, 1999
- Public Since
- March 27th, 2000
- No. of Shareholders
- 8,413
- No. of Employees
- 15,700
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 621,751,736
- Address
- 1 Edwards Way, IRVINE, 92614-5688
- Web
- https://www.edwards.com
- Phone
- +1 9492502500
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for EW
Edwards Lifesciences Corp at Sanford C Bernstein Strategic Decisions Conference
Q2 2022 Edwards Lifesciences Corp Earnings Release
Q3 2022 Edwards Lifesciences Corp Earnings Release
Similar to EW
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
AmerisourceBergen
New York Stock Exchange
FAQ
What is the Edwards Lifesciences share price?
As of Today at 19:06 UTC, shares in Edwards Lifesciences are trading at $96.13. This share price information is delayed by 15 minutes.
How has the Edwards Lifesciences share price performed this year?
Shares in Edwards Lifesciences last closed at $96.13 and the price had moved by +2.05% over the past 365 days. In terms of relative price strength the Edwards Lifesciences share price has outperformed the S&P500 Index by +7.78% over the past year.
What are the analyst and broker recommendations for Edwards Lifesciences?
The overall consensus recommendation for Edwards Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Edwards Lifesciences dividend yield?
Edwards Lifesciences does not currently pay a dividend.
Does Edwards Lifesciences pay a dividend?
Edwards Lifesciences does not currently pay a dividend.
When does Edwards Lifesciences next pay dividends?
Edwards Lifesciences does not currently pay a dividend.
How do I buy Edwards Lifesciences shares?
To buy shares in Edwards Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Edwards Lifesciences?
As of the previous close price of $96.13, shares in Edwards Lifesciences had a market capitalisation of $59.77bn.
Where are Edwards Lifesciences shares listed?
Here are the trading details for Edwards Lifesciences:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: EW
What kind of share is Edwards Lifesciences?
Based on an overall assessment of its quality, value and momentum Edwards Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Edwards Lifesciences share price forecast for 2022?
The analyst consensus target price for shares in Edwards Lifesciences is $127.40. That is 32.53% above the last closing price of $96.13.
Analysts covering Edwards Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of $2.57 for the next financial year.
What is the trend in the Edwards Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edwards Lifesciences. Over the past six months, its share price has underperformed the S&P500 Index by -2.92%.
As of the last closing price of $96.13, shares in Edwards Lifesciences were trading -15.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Edwards Lifesciences PE Ratio?
The Edwards Lifesciences PE ratio based on its reported earnings over the past 12 months is 35.89. The shares last closed at $96.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Edwards Lifesciences?
Edwards Lifesciences' management team is headed by:
- Michael Mussallem - CHM
- Scott Ullem - CFO
- Jean-Luc Lemercier - CEX
- Donald Bobo - VPR
- Daveen Chopra - VPR
- Catherine Szyman - VPR
- Huimin Wang - VPR
- Larry Wood - VPR
- Martha Marsh - LED
- Kieran Gallahue - IND
- Leslie Heisz - IND
- Paul LaViolette - IND
- Steven Loranger - IND
- Ramona Sequeira - IND
- Nicholas Valeriani - IND